Vor Bio is narrowing its focus to a two-indication strategy. The most notable strategic choice is the prioritization of myasthenia gravis (MG) and Sjögren's syndrome as the main indications. The company is deprioritizing lupus. These changes were announced at JPM26. The strategic decision involves focusing on two key areas of development.